These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 25119184)

  • 1. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
    Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.
    Quartino AL; Li H; Jin JY; Wada DR; Benyunes MC; McNally V; Viganò L; Nijem I; Lum BL; Garg A
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):353-361. PubMed ID: 28074265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.
    Bruno R; Washington CB; Lu JF; Lieberman G; Banken L; Klein P
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):361-9. PubMed ID: 15868146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR.
    Sharma S; Mittapalli RK; Holen KD; Xiong H
    Clin Pharmacokinet; 2015 Oct; 54(10):1071-81. PubMed ID: 25761639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
    Wang B; Deng R; Hennig S; Badovinac Crnjevic T; Kaewphluk M; Kågedal M; Quartino AL; Girish S; Li C; Kirschbrown WP
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):499-512. PubMed ID: 34106303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.
    Ng CM; Lum BL; Gimenez V; Kelsey S; Allison D
    Pharm Res; 2006 Jun; 23(6):1275-84. PubMed ID: 16715358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
    Narwal R; Roskos LK; Robbie GJ
    Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
    Quartino AL; Hillenbach C; Li J; Li H; Wada RD; Visich J; Li C; Heinzmann D; Jin JY; Lum BL
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):77-88. PubMed ID: 26645407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin
    Quartino AL; Li H; Kirschbrown WP; Mangat R; Wada DR; Garg A; Jin JY; Lum B
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):329-340. PubMed ID: 30467591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.
    Xiang H; Liu L; Gao Y; Ahene A; Collins H
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):899-910. PubMed ID: 34383128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
    Gupta M; Lorusso PM; Wang B; Yi JH; Burris HA; Beeram M; Modi S; Chu YW; Agresta S; Klencke B; Joshi A; Girish S
    J Clin Pharmacol; 2012 May; 52(5):691-703. PubMed ID: 21953571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
    Fabre MA; Fuseau E; Ficheux H
    J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.
    Farrell C; Schweizer C; Wustner J; Weil S; Namiki M; Nakano T; Nakai K; Phillips MD
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):727-34. PubMed ID: 22955257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.
    Attard G; Kitzen J; Blagden SP; Fong PC; Pronk LC; Zhi J; Zugmaier G; Verweij J; de Bono JS; de Jonge M
    Br J Cancer; 2007 Nov; 97(10):1338-43. PubMed ID: 18000498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.
    Bastida C; Ruiz-Esquide V; Pascal M; de Vries Schultink AHM; Yagüe J; Sanmartí R; Huitema ADR; Soy D
    Br J Clin Pharmacol; 2018 Apr; 84(4):716-725. PubMed ID: 29314183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.
    Cortés J; Swain SM; Kudaba I; Hauschild M; Patel T; Grincuka E; Masuda N; McNally V; Ross G; Brewster M; Marier JF; Trinh MM; Garg A; Nijem I; Visich J; Lum BL; Baselga J
    Anticancer Drugs; 2013 Nov; 24(10):1084-92. PubMed ID: 23969513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
    Zheng B; Yu XQ; Greth W; Robbie GJ
    Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.